Equities

Kalvista Pharmaceuticals Inc

Kalvista Pharmaceuticals Inc

Actions
  • Price (EUR)9.70
  • Today's Change0.20 / 2.11%
  • Shares traded0.00
  • 1 Year change+10.86%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Apr 30 2024202420232022
ASSETS
Cash And Short Term Investments210149166
Total Receivables, Net111914
Total Inventory------
Prepaid expenses4.424.3113
Other current assets, total------
Total current assets226172194
Property, plant & equipment, net9.151110
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.570.110.19
Total assets235183204
LIABILITIES
Accounts payable9.114.823.64
Accrued expenses14107.94
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total------
Total current liabilities231512
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total6.027.157.21
Total liabilities292219
SHAREHOLDERS EQUITY
Common stock0.040.030.03
Additional paid-in capital680507439
Retained earnings (accumulated deficit)(470)(343)(250)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(3.49)(3.06)(3.86)
Total equity207161185
Total liabilities & shareholders' equity235183204
Total common shares outstanding433425
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.